Clinical Oversight Review Board (CORB) Criteria for Prescribing

Tildrakizumab-asmn (Ilumya)


Non-Formulary **tildrakizumab-asmn (Ilumya)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

<u>Initiation (new start) criteria</u>: Non-formulary tildrakizumab-asmn (Ilumya) will be covered on the prescription drug benefit when the following criteria are met:

- Prescriber is a dermatologist and patient has a diagnosis of plaque psoriasis
- Patient has tried and failed/intolerant to at least 2 of the following:
 - Infliximab product
 - Adalimumab (criteria based)
 - Etanercept (criteria based)
- Patient has tried and failed/intolerant to or has a contraindication to all of the following:
 - Secukinumab (criteria based)
 - Ustekinumab (criteria based)
 - Apremilast (criteria based)
 - Guselkumab (criteria based)
 - Risankizumab-rzaa (criteria based)

kp.org

Revised: 02/13/20 Effective: 03/19/20





All plans offered and underwritten by